Australia
Brazil
Canada
Germany
India
Ireland
Japan
Mexico
New Zealand
Philippines
South Africa
United Kingdom
The Biotech Startups Podcast
Also in Life Sciences
Science
BioCentury This Week
by BioCentury
Today: #101 in Science, United Kingdom on our combined chart.
Today: #41 in Science, New Zealand on our combined chart.
Chart positions today · United States
Not on the United States charts we track today.
Not on the Canada charts we track today.
Not on the Australia charts we track today.
Not on the Germany charts we track today.
Not on the Brazil charts we track today.
Not on the Mexico charts we track today.
Not on the Ireland charts we track today.
Not on the India charts we track today.
Not on the Japan charts we track today.
Not on the Philippines charts we track today.
Not on the South Africa charts we track today.
If you like BioCentury This Week, try…
Biotech Hangout
Similar topics: biotech and fda
The Pharma Closeout | Daily Pharmaceutical and Biotech News in 15 Minutes
Also in Life Sciences
Cancer Connections
Also in Life Sciences
Approved
Also in Life Sciences
Clinical Pharmacology Podcast with Nathan Teuscher
Also in Life Sciences
Ranking history · United States
Latest daily rankings: Oct 31. New rankings will appear after the next update.
Recent history only — this show has no current ranking on the Science chart. These are recorded positions from the last 14 days, not current rankings.
Position on the Science combined chart over the last 14 days. Toggle platforms to compare their positions. Lower rank numbers are better.
Episode releases
View as table
| Date | Combined Rank | Apple Podcasts | Castbox |
|---|---|---|---|
| Oct 31 | — | — | — |
| Oct 30 | — | #190 | — |
| Oct 29 | #175 | #160 | — |
| Oct 28 | #145 | #129 | — |
| Oct 27 | #186 | #173 | — |
| Oct 26 | #196 | #183 | — |
| Oct 25 | #167 | #153 | — |
| Oct 24 | #161 | #147 | — |
| Oct 23 | #125 | #112 | #100 |
| Oct 22 | #94 | #72 | #71 |
| Oct 21 | #93 | #72 | #72 |
| Oct 20 | #92 | #67 | #60 |
| Oct 19 | #95 | #68 | #65 |
| Oct 18 | #92 | #63 | — |
Latest episodes
-
Ep. 394 - Security concerns in U.S., China reshaping biotech
October 27, 2026 · 34 minProposed U.S. Treasury rules implementing the COINS Act would bar U.S. equity investments, joint ventures and co-development deals with China biotechs, potentially ensnaring Asia-to-West NewCos while leaving licensing intact. On the latest…
-
Ep. 393 - China trends; Roche, Merck KGaA deals; Arrowhead & tau
October 20, 2026 · 30 minRoche’s $15 billion biobucks deal with Hansoh for preclinical ADCs is the latest in a string of China licensing deals carrying unusually large upfronts for early-stage assets. On the latest BioCentury This Week podcast, BioCentury’s…
-
Ep. 392 - Biotech markets: Pause before the storm?
October 13, 2026 · 25 minAn M&A-fueled first half gave way to third-quarter underperformance for biotech as a short squeeze in Moderna forced specialist funds into selling some quality names and follow-on activity slowed. On the latest BioCentury This Week…
-
Ep. 391 - China deals, Beam lawsuit, MFN models, Nobel winners
October 6, 2026 · 30 minPharma partnering in China is getting earlier and broader, with Merck & Co., Novo Nordisk and Novartis striking multibillion-dollar deals for assets spanning new modalities and disease areas. On the latest BioCentury This Week podcast…
-
Ep. 390 - Live from Amsterdam: Grand Rounds Europe takeaways
September 30, 2026 · 34 minMechanisms broad enough to matter across many diseases, from mitochondrial health to the biology of aging, emerged as a defining theme at Grand Rounds Europe in Amsterdam. On a special live edition of the BioCentury This Week podcast…
Show 7 more episodesShow fewer episodes
-
Ep. 389 - IgA nephropathy, Overton hearing, reverse mergers' new look
September 29, 2026 · 37 minSeven global approvals in five years, validated biomarkers and FDA flexibility have turned IgA nephropathy from a neglected rare disease into a crowded field, with Biogen, Novartis, Takeda, Climb Bio and Jade chasing targets such as APRIL…
-
Ep. 388 - Biotech IPOs, CAR T safety & pharma tariffs
September 22, 2026 · 32 minThe first biotech IPO in a month, Electra's upsized $350 million offering, fell in its trading debut, testing investor appetite while a wave of reverse mergers showcases an alternate route to NASDAQ. On the latest BioCentury This Week…
-
Ep. 387 - Psychedelics at FDA, Mike Davis’ CDER & tRNAs
September 15, 2026 · 31 minNote: This episode was briefly published with an incorrect audio file, which has since been corrected. FDA is prepared to approve psychedelic therapies for chronic psychiatric disorders before sponsors have fully determined how long the…
-
Ep. 386 - Novartis misses, pharma deals analysis, MFN carve-outs
September 9, 2026 · 35 minA pair of high profile clinical setbacks has wiped out more than $40 billion in market cap for Novartis, most of which stemmed from the Phase III miss of antisense oligonucleotide therapy pelacarsen. On the latest BioCentury This Week…
-
Ep. 385 - MFN deals, Lilly takeout, FDA pick Overton
September 1, 2026 · 36 minMid-sized biopharma companies are under growing pressure to accept most-favored nation drug pricing deals with the White House. On the latest BioCentury This Week podcast, BioCentury's analysts assess the trade-offs companies face, the…
-
Ep. 384 - Back to School Special: The global FIH trials race
August 28, 2026 · 43 minChina has changed the global narrative on delivering early human clinical data, with a new bar for speed and efficiency. And now drug developers and policymakers around the world have gotten the message and know that this is no time for…
-
Ep. 383 - Moderna, Genentech obesity deal, Trump's FDA pick
August 25, 2026 · 19 minA Phase III win for a melanoma vaccine from Moderna and Merck & Co. has opened the door to personalized neoantigen vaccines. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the vaccine’s prospects and the broader…
About the show
BioCentury's streaming commentary on biotech industry trends, plus interviews with KOLs.For three decades, BioCentury has helped biopharma executives and investors make business-critical decisions and build larger networks with peers across the innovation ecosystem.